The company operates in over 75 countries, marketing livestock breeding products under the ‘ABS’ (cattle) and ‘PIC’ (pigs) brands.
The group highlights include strong underlying group trading, with ABS performing ahead of expectations. Phase 2 of Genus’s investment strategy realised an £8.5 million benefit. Americas and Asia regions showed continued strong performance.
Genus received a £3.7 million net benefit following the U.S. FDA’s approval of its PRRS2 Resistant Pig gene edit for use in US food supply.
This includes a $5.5 million (£4.1 million) milestone payment from Chinese partner Beijing Capital Agribusiness.
Genus continues to lead innovation in genetic improvement for livestock, supporting global food production.